Arrayit Corporation, headquartered in Sunnyvale, California, operates as a global life sciences technology firm. The company is dedicated to developing, manufacturing, and commercializing advanced tools and integrated systems for comprehensive analysis of genetic variations, biological functions, and diagnostic applications worldwide. Its core activities encompass the creation and maintenance of microarray instruments and components, providing bespoke microarray printing and analysis services for research, and pioneering diagnostic microarrays designed for the early identification of treatable health conditions. Arrayit's innovative microarray printing technology facilitates the production of diverse microarray types—including DNA, protein, antibody, lipid, and carbohydrate—suitable for a wide array of research and diagnostic uses such as gene expression studies, genotyping, and protein profiling. The company's product portfolio extends to automated microarray manufacturing instruments like the NanoPrint, various SpotBot models (Titan, Extreme, Protein), and Personal microarrayers. It also supplies a range of scanning devices, including SpotLight CCD and SpotWare colorimetric scanners, InnoScan laser scanners, alongside hybridization stations (TrayMix, ArrayMix), centrifuges, air jets, vacuum equipment, general laboratory tools, and bioinformatics computing solutions. Additionally, Arrayit manufactures essential consumables such as glass substrates and slides, reagents, solutions, kits, and clean room provisions. A notable offering is its variation identification platform technology, which enables diagnostic tests by accommodating approximately 100,000 patient samples on a single microarray. The company further diversifies its operations through the import, export, manufacture, and distribution of wholesale industrial chemicals. Arrayit Corporation serves a broad spectrum of clients, including genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology firms.